Zentalis Pharmaceuticals Promotes Co-Founder Kevin Bunker, Ph.D. to Chief Scientific OfficerGlobeNewsWire • 09/27/22
Zentalis Pharmaceuticals Appoints Dr. Carrie Brownstein as Chief Medical OfficerGlobeNewsWire • 09/19/22
Zentalis Pharmaceuticals, Inc. (ZNTL) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 08/26/22
Does Zentalis Pharmaceuticals, Inc. (ZNTL) Have the Potential to Rally 129% as Wall Street Analysts Expect?Zacks Investment Research • 08/16/22
Why Zentalis Pharmaceuticals (ZNTL) Might Surprise This Earnings SeasonZacks Investment Research • 08/10/22
Zentalis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational UpdateGlobeNewsWire • 08/09/22
Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare ConferenceGlobeNewsWire • 08/03/22
Zentalis Pharmaceuticals, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 08/01/22
Zentalis Pharmaceuticals Appoints Andrea Paul as General Counsel and Corporate SecretaryGlobeNewsWire • 06/27/22
Zentalis Pharmaceuticals Announces Closing of Underwritten Offering of Common StockGlobeNewsWire • 05/18/22
Zentalis Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational UpdateGlobeNewsWire • 05/05/22
Here's Why Zentalis Pharmaceuticals, Inc. (ZNTL) is Poised for a Turnaround After Losing 50% in 4 WeeksZacks Investment Research • 04/19/22
Zentalis Pharmaceuticals Announces Overview of Clinical and Preclinical Data Presented at AACRGlobeNewsWire • 04/11/22
Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-c3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACRGlobeNewsWire • 04/08/22
Zentalis Pharmaceuticals to Present at the Oppenheimer Annual Healthcare ConferenceGlobeNewsWire • 03/09/22
Zentalis Pharmaceuticals to Present New Clinical and Preclinical Data at the AACR Annual Meeting 2022GlobeNewsWire • 03/08/22
Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational UpdateGlobeNewsWire • 02/24/22
Zentalis Pharmaceuticals to Host Virtual Research and Development (R&D) Day on December 16, 2021GlobeNewsWire • 12/02/21
Zentalis Pharmaceuticals Announces Fast Track Designation Granted by the U.S. FDA to ZN-c3 for the Treatment of Uterine Serous CarcinomaGlobeNewsWire • 11/17/21
Zentalis Pharmaceuticals Announces First Patient Dosed in the Phase 1/2 Study of ZN-c3 in Combination with Gemcitabine in Patients with OsteosarcomaGlobeNewsWire • 09/13/21
Zentalis Pharmaceuticals Announces Publication in the Journal of Medicinal Chemistry Highlighting the Discovery of its WEE1 Inhibitor Candidate ZN-c3GlobeNewsWire • 09/01/21